# Identifying Novel Senolytic Agents and Molecular Targets

> **NIH NIH R56** · UNIVERSITY OF FLORIDA · 2020 · $378,140

## Abstract

PROJECT SUMMARY/ABSTRACT
Cellular senescence is an important fundamental mechanism of aging and age-related diseases. It has been
demonstrated that genetic elimination of senescent cells (SCs) can dramatically alleviate aging-related
phenotypes and extend both healthspan and lifespan in mice. Senolytics, referring to small-molecules that can
selectively induce apoptosis in SCs, thus have the potential to be developed as “anti-aging” drugs that extend
human healthspan by preventing or treating age-related diseases. We and others have recently discovered a
number of senolytics that target various SC anti-apoptotic pathways (SCAPs). Subsequent studies on these
senolytics in animal models have shown that clearance of SCs can treat several age-related diseases and
chemo-/radio-therapy caused adverse effects in mice, thus demonstrating the therapeutic potential of
senolytics. However, most of the reported senolytics have potential on-target and off-target toxicities. In
addition, SCs are not all the same; different SCs may use different SCAPs to resist apoptosis. Thus, it is
important to continue the search of new SCAPs/protein targets and new senolytics. Piperlongumine (PL), a
dietary natural product, was identified as a novel senolytic agent through our targeted screening campaign. PL
appears to be safe, without observable toxicity in vivo and having a high maximum tolerated oral dose in mice.
However, its mechanism of action (MOA) against SC is undefined, raising the potential of discovering novel
molecular targets for senolytic drug development. Therefore, we hypothesize that PL can be used to identify
new molecular targets in SCs, which can then be exploited for the development of novel and specific senolytics.
Our preliminary structure–activity relationship (SAR) studies have identified PL analogues (piperlogues) with
senolytic profile comparable to that of ABT263, one of the most potent and selective senolytics identified to
date, and also designed and synthesized PL-based probe molecules for the pulldown of target proteins in SCs.
With proteomics analyses and RNAi technology, we identified, validated, and characterized oxidation protein 1
(OXR1) as one of the protein targets of PL in SCs. The objectives of this application are to continue the
discovery and evaluation of piperlogues as potent and selective senolytics, identification of their molecular
targets, and elucidation of the MOA of these novel agents. Specifically, we will pursue the following specific
aims: 1) design, synthesize, and evaluate novel piperlogues with improved senolytic activity and druglike
properties; 2) identify and validate the protein targets of PL and piperlogues in SCs, and elucidate their MOA;
and 3) evaluate the in vivo efficacy and safety of lead piperlogues. Success in these proposed aims will not
only produce anti-aging drug development candidates but also identify and validate additional novel molecular
target(s) to enable future design and target-based discov...

## Key facts

- **NIH application ID:** 10229301
- **Project number:** 1R56AG065635-01
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **Principal Investigator:** Guangrong Zheng
- **Activity code:** R56 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $378,140
- **Award type:** 1
- **Project period:** 2020-09-30 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10229301

## Citation

> US National Institutes of Health, RePORTER application 10229301, Identifying Novel Senolytic Agents and Molecular Targets (1R56AG065635-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10229301. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*